Understanding Tobacco And Tobacco Harm Reduction: A Path Forward

      Date
      Jul 1, 2013 - Jul 1, 2013
      Location
      Intercontinental Soeul Coex, Bongeunsa-ro, Gangnam-gu, Seoul, 135-975, South Korea
      Developing and commercializing reduced risk tobacco products has been one of PMI’s top priorities for many years. Underlying the development of these products is the need for scientific validation of the risk reduction potential of such products. PMI would like to share with you how Toxicology and Systems Biology are helping the company meet this significant challenge. During the symposium, PMI scientists will present their research on Toxicology and Systems Biology approaches.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.